ArticleFrontiers in neurology2025
Disease burden of myasthenia gravis in relation to oral corticosteroid dose: an insurance claims database study in Japan.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treatment Patterns in Patients with Late-Onset Myasthenia Gravis in Japan: An Insurance Claims Database Study.Drugs - real world outcomes · 2026Article
- Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France.Journal of neuromuscular diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oral corticosteroids (OCS) are used for maintenance treatment of myasthenia gravis (MG). Prolonged use of higher-dose OCS may provoke serious adverse events. Therefore, Japanese clinical guidelines recommend an OCS dose target of ≤5 mg/day. This retrospective study aimed to compare the burden of MG between patients achieving this target and non-achievers. Methods: Data were obtained from three Japanese healthcare databases (JMDC, NHI and LSEHS) between 2014 and 2021. Patients with MG starting immunotherapy were enrolled and data were collected over 2 years following start of immunotherapy. Exposure to OCS was determined from medication delivery records; achievers and non-achievers of the ≤5 mg/day target during follow-up were identified. Outcomes evaluated were confirmed incident diabetes, new osteoporotic fracture, and total and MG-related costs. Results: Overall, 459 patients were analyzed. Of these, 94 patients (58.4%) in the JMDC population, 96 (64.0%) in the NHI population and 119 (80.4%) in the LSEHS population achieved the ≤5 mg/day target. Incident confirmed diabetes in the JMDC population and new osteoporotic fractures in the LSEHS population were less frequent in target achievers than in non-achievers ( Discussion: OCS dose target non-achievers carry a higher burden than achievers. Broader implementation of effective treatment strategies is required to reduce long-term use of higher-dose OCS and the associated burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.